Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME 11:39:57 2024-09-10 EDT Pre-market 02:13:19
9.228 EUR -0.75% Intraday chart for Grifols, S.A. 9.394 +1.80%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Grifols Shareholders Tap Spanish Law Group to Ensure Substantial Premium in Brookfield's Offer MT
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Index Set to End Week 3.7% Lower MT
European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading MT
Grifols indefinitely postpones October 10 investor day RE
European Equities Traded in the US as American Depositary Receipts Edge Lower Friday; Set to End Week Up 0.5% MT
Brookfield in Talks to Partner With Sovereign Funds For Grifols Offer MT
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid CI
Brookfield in Talks With Sovereign Funds to Join Grifols Acquisition Bid MT
Brookfield in Talks With Sovereign Funds to Join Grifols Acquisition Bid MT
Brookfield in Talks With Sovereign Funds to Join Grifols Acquisition Bid, Bloomberg Reports MT
Biotest Chief Scientific Officer to Step Down MT
European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
Sector Update: Health Care Stocks Edge Up Late Afternoon MT
Sector Update: Health Care Stocks Rise Wednesday Afternoon MT
Sector Update: Health Care MT
Brookfield in talks with banks for funding Grifols' takeover bid, sources say RE
European Equities Close Mostly Higher in Wednesday Trading; CMA Closes Probes Into Google, Apple MT
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading MT
Brookfield Seeks Financing Ahead of Effort to Take Grifols Private MT
Brookfield Eyes EUR9.5 Billion Bank Debt for Potential Grifols Deal MT
Chart Grifols, S.A.
More charts
Logo Grifols, S.A.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Employees
23,505
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
9.228EUR
Average target price
17.72EUR
Spread / Average Target
+92.02%
Consensus
  1. Stock Market
  2. Equities
  3. GRF Stock
  4. News Grifols, S.A.
  5. Grifols Shares Surge on Take-Private Talks
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW